Movement Disorders from the Use of Metoclopramide and Other Antiemetics in the Treatment of Migraine

Headache

Volumn 56, Issue 1, 2016, Pages 153-161

  Wijemanne, Subhashie ^a   Jankovic, Joseph ^a   Evans, Randolph W ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

acute dystonic reaction; akathisia; metoclopramide; migraine; prochlorperazine; promethazine; tardive dyskinesia

Indexed keywords

AMANTADINE; ANTIEMETIC AGENT; BOTULINUM TOXIN; DIHYDROERGOTAMINE; DIPHENHYDRAMINE; DOMPERIDONE; METOCLOPRAMIDE; ONDANSETRON; PARACETAMOL; PROCHLORPERAZINE; PROMETHAZINE; TETRABENAZINE; TRIMETHOBENZAMIDE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT;

ABNORMAL POSTURE; ACUTE AKATHISIA; ADULT; AKATHISIA; CASE REPORT; CERVICAL DYSTONIA; DISEASE EXACERBATION; DRUG INDUCED DISEASE; DYSTONIA; FEMALE; HOSPITALIZATION; HUMAN; MIGRAINE; MOTOR DYSFUNCTION; NAUSEA AND VOMITING; NEUROLEPTIC MALIGNANT SYNDROME; PAIN INTENSITY; PARKINSONISM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; TARDIVE DYSKINESIA; TARDIVE DYSTONIA; TRANSFORMED MIGRAINE; TREATMENT DURATION; EXPERT WITNESS; MIGRAINE DISORDERS; MOVEMENT DISORDERS;

ADULT; DIHYDROERGOTAMINE; DOPAMINE AGONISTS; DOPAMINE D2 RECEPTOR ANTAGONISTS; EXPERT TESTIMONY; FEMALE; HUMANS; METOCLOPRAMIDE; MIGRAINE DISORDERS; MOVEMENT DISORDERS;

EID: 84956581812     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/head.12712     Document Type: Review

References (68)

1. Kelley NE, Tepper DE., Rescue therapy for acute migraine, part 2: Neuroleptics, antihistamines, and others. Headache. 2012; 52: 292-306.
2. Hurtado TR, Vinson DR, Vandenberg JT., ED treatment of migraine headache: Factors influencing pharmacotherapeutic choices. Headache. 2007; 47: 1134-1143.
3. Tek DS, McClellan DS, Olshaker JS, Allen CL, Arthur DC., A prospective, double-blind study of metoclopramide hydrochloride for the control of migraine in the emergency department. Ann Emerg Med. 1990; 19: 1083-1087.
4. Ellis GL, Delaney J, DeHart DA, Owens A., The efficacy of metoclopramide in the treatment of migraine headache. Ann Emerg Med. 1993; 22: 191-195.
5. Jones EB, Gonzalez ER, Boggs JG, Grillo JA, Elswick RK Jr., Safety and efficacy of rectal prochlorperazine for the treatment of migraine in the emergency department. Ann Emerg Med. 1994; 24: 237-241.
6. Tanen DA, Miller S, French T, Riffenburgh RH., Intravenous sodium valproate versus prochlorperazine for the emergency department treatment of acute migraine headaches: A prospective, randomized, double-blind trial. Ann Emerg Med. 2003; 41: 847-853.
7. Waln O, Jankovic J., An update on tardive dyskinesia: From phenomenology to treatment. Tremor Other Hyperkinet Mov (N Y). 2013; 3.
8. Bhidayasiri R, Fahn S, Weiner WJ, et al., Evidence-based guideline: Treatment of tardive syndromes: Report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2013; 81: 463-469.
9. Kenney C, Hunter C, Davidson A, Jankovic J., Metoclopramide, an increasingly recognized cause of tardive dyskinesia. J Clin Pharmacol. 2008; 48: 379-384.
10. Factor SA, Jankovic J., Randomized trial of IV valproate vs metoclopramide vs ketorolac for acute migraine. Neurology. 2014; 83: 1388-1389.
11. Akagi H, Kumar TM., Lesson of the week: Akathisia: Overlooked at a cost. BMJ. 2002; 324: 1506-1507.
12. Rodgers C., Extrapyramidal side effects of antiemetics presenting as psychiatric illness. Gen Hosp Psychiatry. 1992; 14: 192-195.
13. Keepers GA, Clappison VJ, Casey DE., Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Arch Gen Psychiatry. 1983; 40: 1113-1117.
14. Arana GW, Goff DC, Baldessarini RJ, Keepers GA., Efficacy of anticholinergic prophylaxis for neuroleptic-induced acute dystonia. Am J Psychiatry. 1988; 145: 993-996.
15. Tarsy D, Indorf G., Tardive tremor due to metoclopramide. Mov Disord. 2002; 17: 620-621.
16. Stacy M, Jankovic J., Tardive tremor. Mov Disord. 1992; 7: 53-57.
17. Melamed E, Achiron A, Shapira A, Davidovicz S., Persistent and progressive parkinsonism after discontinuation of chronic neuroleptic therapy: An additional tardive syndrome? Clinical Neuropharmacol. 1991; 14: 273-278.
18. Erro R, Bhatia KP, Tinazzi M., Parkinsonism following neuroleptic exposure: A double-hit hypothesis? Mov Disord. 2015; 30: 780-785.
19. Miller LG, Jankovic J., Metoclopramide-induced movement disorders. Clinical findings with a review of the literature. Arch Intern Med. 1989; 149: 2486-2492.
20. Wittmann O, Sadot E, Bisker-Kassif O, Scolnik D, Tavor O, Glatstein MM., Neuroleptic malignant syndrome associated with metoclopramide use in a boy: Case report and review of the literature. Am J Ther. 2015 [Epub ahead of print].
21. Modi S, Dharaiya D, Schultz L, Varelas P., Neuroleptic malignant syndrome: Complications, outcomes, and mortality. Neurocrit Care. 2015 [Epub ahead of print].
22. Jankovic J, Tolosa E., Drug Induced Movement Disorders, Chapter 33. Parkinson's Disease and Movement Disorders. Philadelphia, PA: Wolters Kluwer; 2015.
23. Yassa R, Jeste DV., Gender differences in tardive dyskinesia: A critical review of the literature. Schizophr Bull. 1992; 18: 701-715.
24. Shaffer D, Butterfield M, Pamer C, Mackey AC., Tardive dyskinesia risks and metoclopramide use before and after U.S. market withdrawal of cisapride. J Am Pharm Assoc. 2004; 44: 661-665.
25. Jankovic J., Tardive syndromes and other drug-induced movement disorders. Clin Neuropharmacol. 1995; 18: 197-214.
26. Bateman DN, Rawlins MD, Simpson JM., Extrapyramidal reactions with metoclopramide. Br Med J (Clin Res Ed). 1985; 291: 930-932.
27. Segman RH, Heresco-Levy U, Finkel B, et al., Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry. 2001; 6: 225-229.
28. Mahmoudi S, Levesque D, Blanchet PJ., Upregulation of dopamine D3, not D2, receptors correlates with tardive dyskinesia in a primate model. Mov Disord. 2014; 29: 1125-1133.
29. Teo JT, Edwards MJ, Bhatia K., Tardive dyskinesia is caused by maladaptive synaptic plasticity: A hypothesis. Mov Disord. 2012; 27: 1205-1215.
30. Seeman P, Tinazzi M., Loss of dopamine neuron terminals in antipsychotic-treated schizophrenia; relation to tardive dyskinesia. Prog Neuropsychopharmacol Biol Psychiatry. 2013; 44: 178-183.
31. Schwarzberg MN., Application of metoclopramide specificity in migraine attacks therapy. Headache. 1994; 34: 439-441.
32. Colman I, Brown MD, Innes GD, Grafstein E, Roberts TE, Rowe BH., Parenteral metoclopramide for acute migraine: Meta-analysis of randomised controlled trials. BMJ. 2004; 329: 1369-1373.
33. Pasricha PJ, Pehlivanov N, Sugumar A, Jankovic J., Drug insight: From disturbed motility to disordered movement-A review of the clinical benefits and medicolegal risks of metoclopramide. Nat Clin Pract Gastroenterol Hepatol. 2006; 3: 138-148.
34. Ganzini L, Casey DE, Hoffman WF, McCall AL., The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. Arch Intern Med. 1993; 153: 1469-1475.
35. Parlak I, Atilla R, Cicek M, et al., Rate of metoclopramide infusion affects the severity and incidence of akathisia. Emerg Med J. 2005; 22: 621-624.
36. Egerton-Warburton D, Povey K., Administration of metoclopramide by infusion or bolus does not affect the incidence of drug-induced akathisia. Emerg Med Australas. 2013; 25: 207-212.
37. Parlak I, Erdur B, Parlak M, et al., Intravenous administration of metoclopramide by 2 min bolus vs 15 min infusion: Does it affect the improvement of headache while reducing the side effects? Postgrad Med J. 2007; 83: 664-668.
38. LaGorio J, Thompson VA, Sternberg D, Dorje P., Akathisia and anesthesia: Refusal of surgery after the administration of metoclopramide. Anesth Analg. 1998; 87: 224-227.
39. Chow LY, Chung D, Leung V, Leung TF, Leung CM., Suicide attempt due to metoclopramide-induced akathisia. Int J Clin Pract. 1997; 51: 330-331.
40. Cete Y, Dora B, Ertan C, Ozdemir C, Oktay C., A randomized prospective placebo-controlled study of intravenous magnesium sulphate vs. metoclopramide in the management of acute migraine attacks in the emergency department. Cephalalgia. 2005; 25: 199-204.
41. Abell TL, Bernstein RK, Cutts T, et al., Treatment of gastroparesis: A multidisciplinary clinical review. Neurogastroenterol Motil. 2006; 18: 263-283.
42. Parkman HP, Hasler WL, Fisher RS., American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology. 2004; 127: 1592-1622.
43. Rao AS, Camilleri M., Review article: Metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther. 2010; 31: 11-19.
44. Friedman LS, Weinrauch LA, D'Elia JA., Metoclopramide-induced neuroleptic malignant syndrome. Arch Intern Med. 1987; 147: 1495-1497.
45. Robinson MB, Kennett RP, Harding AE, Legg NJ, Clarke B., Neuroleptic malignant syndrome associated with metoclopramide. J Neurol Neurosurg Psychiatry. 1985; 48: 1304.
46. Friedman BW, Mulvey L, Esses D, et al., Metoclopramide for acute migraine: A dose-finding randomized clinical trial. Ann Emerg Med. 2011; 57: 475-482 e471.
47. Miller MA, Levsky ME, Enslow W, Rosin A., Randomized evaluation of octreotide vs prochlorperazine for ED treatment of migraine headache. Am J Emerg Med. 2009; 27: 160-164.
48. Drotts DL, Vinson DR., Prochlorperazine induces akathisia in emergency patients. Ann Emerg Med. 1999; 34: 469-475.
49. Vinson DR, Drotts DL., Diphenhydramine for the prevention of akathisia induced by prochlorperazine: A randomized, controlled trial. Ann Emerg Med. 2001; 37: 125-131.
50. Vinson DR, Migala AF, Quesenberry CP Jr., Slow infusion for the prevention of akathisia induced by prochlorperazine: A randomized controlled trial. J Emerg Med. 2001; 20: 113-119.
51. Friedman BW, Esses D, Solorzano C, et al., A randomized controlled trial of prochlorperazine versus metoclopramide for treatment of acute migraine. Ann Emerg Med. 2008; 52: 399-406.
52. Mendhekar DN, Andrade C., Prochlorperazine-induced tardive dystonia and its worsening with clozapine in a non-mentally ill patient with migraine. Ann Pharmacother. 2011; 45: 545-546.
53. Asadollahi S, Heidari K, Vafaee R, Forouzanfar MM, Amini A, Shahrami A., Promethazine plus sumatriptan in the treatment of migraine: A randomized clinical trial. Headache. 2014; 54: 94-108.
54. U.S. Food and Drug Administration. Reglan (metoclopramide) Tablets, ODT (Orally Disintegrating Tablets), and Injection. 2010. http://wwwfdagov/Safety/MedWatch/SafetyInformation/ucm170934htm.
55. Friedman BW, Bender B, Davitt M, et al., A randomized trial of diphenhydramine as prophylaxis against metoclopramide-induced akathisia in nauseated emergency department patients. Annals Emerg Med. 2009; 53: 379-385.
56. Vinson DR., Diphenhydramine in the treatment of akathisia induced by prochlorperazine. J Emerg Med. 2004; 26: 265-270.
57. Jankovic J, Beach J., Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology. 1997; 48: 358-362.
58. Jankovic J, Clarence-Smith K., Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. Expert Rev Neurother. 2011; 11: 1509-1523.
59. Muller T., Valbenazine granted breakthrough drug status for treating tardive dyskinesia. Expert Opin Investig Drugs. 2015; 24: 737-742.
60. Damier P, Thobois S, Witjas T, et al., Bilateral deep brain stimulation of the globus pallidus to treat tardive dyskinesia. Arch Gen Psychiatry. 2007; 64: 170-176.
61. Mejia NI, Jankovic J., Tardive dyskinesia and withdrawal emergent syndrome in children. Expert Rev Neurother. 2010; 10: 893-901.
62. Jeste DV, Lohr JB, Clark K, Wyatt RJ., Pharmacological treatments of tardive dyskinesia in the 1980s. J Clin Psychopharmacol. 1988; 8: 38S-48S.
63. Gruppo LQ Jr., Intravenous Zofran for headache. J Emerg Med. 2006; 31: 228-229.
64. Singh V, Sinha A, Prakash N., Ondansetron-induced migraine-type headache. Can J Anaesth. 2010; 57: 872-873.
65. Veneziano M, Framarino Dei Malatesta M, Bandiera AF, Fiorelli C, Galati M, Paolucci A., Ondansetron-induced headache. Our experience in gynecological cancer. Eur J Gynaecol Oncol. 1995; 16: 203-207.
66. MacGregor EA, Wilkinson M, Bancroft K., Domperidone plus paracetamol in the treatment of migraine. Cephalalgia. 1993; 13: 124-127.
67. Waelkens J., Dopamine blockade with domperidone: Bridge between prophylactic and abortive treatment of migraine? A dose-finding study. Cephalalgia. 1984; 4: 85-90.
68. Worthington I, Pringsheim T, Gawel MJ, et al., Canadian Headache Society guideline: Acute drug therapy for migraine headache. Can J Neurol Sci. 2013; 40: S1-S80.